| scholarly article | Q13442814 |
| P50 | author | Maria A. Hawkins | Q43111028 |
| P2093 | author name string | Rosie Cooke | |
| Maxwell Robinson | |||
| Séan M O'Cathail | |||
| Kwun-Ye Chu | |||
| Frank Van Den Heuvel | |||
| Philip Camilleri | |||
| P2860 | cites work | Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review | Q27012449 |
| Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors | Q34135022 | ||
| Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer | Q34575077 | ||
| Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy | Q34771688 | ||
| Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry | Q35646076 | ||
| LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective | Q36235727 | ||
| Stereotactic body radiotherapy (SBRT) for high-risk central pulmonary metastases. | Q36625439 | ||
| Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree | Q37151785 | ||
| A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer | Q38790915 | ||
| Stereotactic Ablative Body Radiotherapy for Lung Metastases: Where is the Evidence and What are We Doing With It? | Q39348312 | ||
| IGRT and motion management during lung SBRT delivery. | Q39396415 | ||
| Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis. | Q51004873 | ||
| Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with "Ultracentral" Non-Small Cell Lung Cancer. | Q52144088 | ||
| Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors. | Q53496956 | ||
| Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus. | Q53518246 | ||
| Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non-Small-Cell Lung Cancer. | Q53631923 | ||
| Ultracentral Tumors Treated With Stereotactic Body Radiotherapy: Single-Institution Experience | Q57133002 | ||
| SUNSET: Stereotactic Radiation for Ultracentral Non-Small-Cell Lung Cancer-A Safety and Efficacy Trial | Q57141292 | ||
| Outcomes of Stereotactic Ablative Radiotherapy for Centrally Located Early-Stage Lung Cancer | Q59587430 | ||
| Stereotactic body radiotherapy for centrally-located lung tumors with 56 Gy in seven fractions: A retrospective study. | Q64917835 | ||
| Stereotactic MR-Guided Online Adaptive Radiation Therapy (SMART) for Ultracentral Thorax Malignancies: Results of a Phase 1 Trial. | Q64956876 | ||
| The safety and effectiveness of stereotactic body radiotherapy for central versus ultracentral lung tumors | Q90514732 | ||
| Is stereotactic body radiotherapy for ultra-central lung tumor a feasible option? A systemic review and meta-analysis | Q91193094 | ||
| Stereotactic body radiotherapy of central lung malignancies using a simultaneous integrated protection approach : A prospective observational study | Q91248808 | ||
| Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial | Q92820082 | ||
| Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial | Q93080682 | ||
| Tumor Control and Toxicity after SBRT for Ultracentral, Central, and Paramediastinal Lung Tumors | Q93369476 | ||
| P304 | page(s) | 24-30 | |
| P577 | publication date | 2020-02-17 | |
| P1433 | published in | Technical Innovations & Patient Support in Radiation Oncology | Q50817414 |
| P1476 | title | Stereotactic body radiotherapy for moderately central and ultra-central oligometastatic disease: Initial outcomes | |
| P478 | volume | 13 |
| Q99582784 | Dose-response relationship of stereotactic body radiotherapy for ultracentral tumor and comparison of efficacy with central tumor: a meta-analysis | cites work | P2860 |
Search more.